title: Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review.
abstract: Hepatocellular carcinoma is the most common form of liver cancer, representing 70% to 85% of primary hepatic malignancies in adults. Liver transplant is an optimal treatment for patients with hepatocellular carcinoma because it eliminates the malignancy as well as the often-underlying liver cirrhosis and restores normal liver function. Since the development of strict selection criteria in hepatocellular carcinoma patients undergoing liver transplant with the implementation of the Milan criteria, patient survival and recurrence rates after liver transplant have dramatically improved. However, several research groups are now seeking to expand this criteria to include more patients with larger tumors who may achieve similar postliver transplant survival rates as those patients meeting current eligibility requirements. Currently, in approximately 20% of patients, hepatocellular carcinoma recurrence is still the rate-limiting event that clearly affects patient survival. Given the limited number of grafts available for transplant, the poor prognosis of untreated hepatocellular carcinoma, and the recent notion of expanding selection criteria, strategies for reducing the rate of, monitoring and treating hepatocellular carcinoma recurrence, in both pretransplants and posttransplants, are explored in this review. We review the available literature to better understand current strategies available to optimize long-term clinical outcomes.
authors.affiliation: Department of Medicine, University of California at Los Angeles, UCLA Medical Center, Los Angeles, CA, USA.
authors.forename: Joshua
authors.initials: J
authors.lastname: Rubin
authors.forename: Noel
authors.initials: N
authors.lastname: Ayoub
authors.forename: Fady
authors.initials: F
authors.lastname: Kaldas
authors.forename: Sammy
authors.initials: S
authors.lastname: Saab
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000517:prevention & control / Q000628:therapy*; D016031:Liver Transplantation; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy*